OKYOOKYO Pharma Limited
The schedule
- Thu15Oct
Should the share price breach the $1.00 minimum bid requirement following financing activities, a formal Nasdaq deficiency notice will introduce a severe structural overhang.
- Tue22Dec
The semi-annual financial update will reflect the aftermath of the expected late-2026 financing and set the baseline for Phase 2 R&D expenditure.
- Sun28Feb
The anticipated commencement of the Phase 2 clinical trial for OKYO's dry eye disease candidate, representing the transition to mid-stage efficacy testing.
Past
- Sat15Aug
Actual outcome: Bull
OKYO secured the necessary capital to fund Phase 2 preparations for OKYO-0101, successfully addressing its dwindling cash reserves. The stock surpassed the $1.50 bull target as the market reacted positively to the removal of the near-term financing overhang, prioritizing the company's improved balance sheet and clinical progression over dilution concerns.
With dwindling cash reserves, a dilutive equity offering or convertible debt issuance is a near-term inevitability to fund Phase 2 preparations for OKYO-0101.
- Wed1Jul
Actual outcome: Bull · $1.64 at outcome
OKYO reported in-line earnings with an EPS of -$0.0691, but the stock rallied 9.3% due to a major pipeline advancement. The company announced positive feedback from an FDA Type D meeting, allowing them to accelerate their lead asset, urcosimod, into a global Phase 3 pivotal trial for neuropathic corneal pain. This significant regulatory progress overshadowed near-term financial concerns and drove the bullish price action.
OKYO is scheduled to release its annual financials. Given the limited cash runway, investors will heavily scrutinize management's commentary on capital adequacy and R&D prioritization for its lead dry eye program.
- Wed29Apr
Crucial feedback from the FDA regarding the Phase 2 efficacy trial design and endpoint structure for OKYO's lead ophthalmology candidate.
